Delving into the Latest Updates on Cromolyn Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cromolyn sodium (USP), DSCG, Disodium Cromoglycate

+ [28]

Target-

Mechanism

Glial cells modulators, Mast cells stabilizers

Therapeutic Areas

Immune System DiseasesEye DiseasesRespiratory Diseases

Active Indication

Food HypersensitivityConjunctivitis, AllergicAsthma

Inactive Indication

Amyotrophic Lateral SclerosisMastocytosisPsoriasis

Originator Organization

Sanofi

Active Organization

Hubei Dongsheng Pharmaceutical Co. Ltd.

King Pharmaceuticals LLCSanofi KK

+ [1]

Inactive Organization

AZTherapies, Inc.

Leo Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

IE (01 Nov 1980),

Asthma

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC23H16Na2O11

InChIKeyAIXRIMKZFKFIAF-UHFFFAOYSA-N

CAS Registry15826-37-6

View All Structures (2)

This is a Phase II, open-label, three-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, or efavirenz) with immune checkpoint inhibitor in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

Start Date30 Jun 2022

Sponsor / Collaborator

Fudan University

NCT05077917 / TerminatedPhase 3IIT

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life.
Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn will be administered as a nebulized treatment four times a day for four days followed by intranasal administration for two weeks. Investigators may also screen for biomarkers that could indicate inflammatory responses and treatment-induced improvement.
Participants will receive either study drug or placebo which will be administered by nebulization for 4 days followed by 14 days of intranasal administration. Participants will be followed while in the hospital and then as outpatients up to day 21 following randomization.

Start Date15 Nov 2021

Sponsor / Collaborator

Texas Tech University Health Sciences Center

ChiCTR2100050716 / RecruitingPhase 4IIT

Efficacy of Sodium Cromoglicate in combination with nasal glucocorticoids in the treatment of drug-induced rhinitis: a multicenter randomized controlled trial

Start Date04 Sep 2021

Sponsor / Collaborator

Yantai Yuhuangding Hospital

100 Clinical Results associated with Cromolyn Sodium

Login to view more data

100 Translational Medicine associated with Cromolyn Sodium

Login to view more data

100 Patents (Medical) associated with Cromolyn Sodium

Login to view more data

2,903

Literatures (Medical) associated with Cromolyn Sodium

01 Dec 2024·Biomaterials Advances

Impacts of industrial food wastes on nutritional value of mealworm (Tenebrio molitor) and its gut microbiota community shift

Article

Author: Loo, Say Chye Joachim ; Yu, Hong ; Feng, Shiliu ; Li, Wenrui

The extensive investigation into the capacity of mealworms to digest diverse food by-products, as well as plastic wastes, has been a focal point in recent years. The transition from traditional diet sources like brans to food wastes has the potential to impact the physiological properties of mealworms. This study explored the utilization of various industrial food wastes such as okara, barley spent grain (BSG), sesame oil meal (SOM), and spent coffee grounds (SCG) as feed alternatives, and reports on their survival rate, biomass variations, and nutritional composition. In additional, the shift in their gut microbiota was also assessed. Among the range of industrial food wastes, mealworms exhibited the most robust growth performance when nourished with BSG. This particular group showed a survival rate of 98.33 % and a biomass increase of 23.06 %. In contrast, mealworms fed with SCG demonstrated the lowest survival rate and experienced a significant reduction in biomass. Although the groups fed with okara and SCG displayed moderate growth performance, both exhibited protein levels comparable to those observed in the oatmeal-fed group (used as the positive control). Notably, the inclusion of BSG in the mealworm diet exhibited the potential to enrich their omega-3 fatty acid content, suggesting potential benefits for applications as animal feed or even human consumption. Furthermore, an analysis of the gut microbiome was conducted to investigate the associations between specific diets and the composition of mealworm gut microbiota. In summary, food wastes such as BSG may be repurposed as feed substrates for mealworms before converting them into an alternative source of protein.

01 Dec 2024·International Journal of Biological Macromolecules

Inflammatory regulation of squid cartilage gelatin with different molecular weights for treatment of chronic wounds in diabetes

Article

Author: Chen, Xiguang ; Zhan, Hao ; Cai, Jingyu ; Mu, Yuzhi ; Feng, Chao ; Sun, Haotong ; Su, Chang ; Zhang, Qichen ; Liu, Jiahao ; Sun, Yunji ; Sun, Xiaojie ; Wan, Qinglan

Squid, as a very important economic marine species, accounts for 5 % of the total catch of fish and cephalopods. The waste from the processing process of squid can be used for collagen extraction, which has great application value in the field of biomedical materials. Here, we obtained squid cartilage gelatin (SCG) with different molecular weights by adjusti.ng the reaction conditions and used for the treatment of chronic wounds in diabetes. SCG extracted at low temperatures and short heating times demonstrated a more intact structure, higher molecular weight, and superior gel stability. Based on cell study and transcriptome analysis, SCG with high molecular weight significantly promoted cell adhesion, because it provided more contact sites for cells, whereas small molecules of SCG could directly reduce inflammation. Animal studies have demonstrated that SCG significantly promotes diabetic wound healing as evidenced by reducing inflammation, inducing vascular regeneration, promoting tissue growth, re-epithelialization, collagen deposition and remodeling. This study elucidated the immunoregulatory mechanisms of SCG with different molecular weights, and validated its potential application in chronic wound healing in diabetes.

01 Oct 2024·Pharmacology Research & Perspectives

Cromolyn sodium and masitinib combination inhibits fibroblast‐myofibroblast transition and exerts additive cell‐protective and antioxidant effects on a bleomycin‐induced in vitro fibrosis model

Article

Author: Kocanci, Fatma Gonca ; Dirol, Hulya ; Göksu, Azize Yasemin

AbstractIdiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrotic lung disease. While recent studies have suggested the potential efficacy of tyrosine kinase inhibitors in managing IPF, masitinib, a clinically used tyrosine kinase inhibitor, has not yet been investigated for its efficacy in fibrotic lung diseases. In a previous study on an in vitro neurodegenerative model, we demonstrated the synergistic antitoxic and antioxidant effects of masitinib combined with cromolyn sodium, an FDA‐approved mast cell stabilizer. This study aims to investigate the anti‐fibrotic and antioxidant effects of the masitinib‐cromolyn sodium combination in an in vitro model of pulmonary fibrosis. Fibroblast cell cultures treated with bleomycin and/or hydrogen peroxide (H2O2) were subjected to masitinib and/or cromolyn sodium, followed by assessments of cell viability, morphological and apoptotic nuclear changes, triple‐immunofluorescence labeling, and total oxidant/antioxidant capacities, besides ratio of Bax and Bcl‐2 mRNA expressions as an indication of apoptosis. The combined treatment of masitinib and cromolyn sodium effectively prevented the fibroblast myofibroblast transition, a hallmark of fibrosis, and significantly reduced bleomycin / H2O2‐induced apoptosis and oxidative stress. This study is the first to demonstrate the additive anti‐fibrotic, cell‐protective, and antioxidant effects of the masitinib‐cromolyn sodium combination in an in vitro fibrosis model, suggesting its potential as an innovative therapeutic approach for pulmonary fibrosis. Combination therapy may be more advantageous in that both drugs could be administered in lower doses, exerting less side effects, and at the same time providing diverse mechanisms of action simultaneously.

100 Deals associated with Cromolyn Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00526	Cromolyn Sodium	D11AH03 R01AC01 R03BC01 A07EB01 S01GX01	DBSALT000985

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Food Hypersensitivity	GB	Aventis Pharmaceuticals, Inc.	01 May 2005
Conjunctivitis, Allergic	CN	Hubei Dongsheng Pharmaceutical Co. Ltd.	01 Jan 1990
Asthma	IE	King Pharmaceuticals LLC	01 Nov 1980

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 1	US	AZTherapies, Inc.	08 Sep 2020
Psoriasis	Phase 1	DE	Leo Pharma, Inc.	01 Nov 2012
Mastocytosis	Phase 1	DE	Leo Pharma, Inc.	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01933464 (CTgov)	Phase 1/2	Rosacea	10	Cromolyn Sodium (Cromolyn)	eajdyikbvb(booyftklic) = iygqzazopm knkghyeppu (nvxbaewmpp, elcepwusmq - ulbkyttlxp) View more	-	30 Jul 2019
				Normal saline (Vehicle)	eajdyikbvb(booyftklic) = szhuakzzyz knkghyeppu (nvxbaewmpp, vrlfrjxpgv - ogatfriphn) View more
UEGW	Not Applicable	Mast Cell Activation Disorders	-	Ketotifen	gkhsxjcmbe(hriezzkuha) = ffvndzbtyi hourndcxil (bvjeewvcrm )	-	01 Oct 2018
				Fexofenadine	gkhsxjcmbe(hriezzkuha) = xgnsgrmmxa hourndcxil (bvjeewvcrm )
ASN2010	Not Applicable	Reperfusion Injury serum creatinine	36	Sodium Cromoglicate 160 mg/kg	myvmxygcqj(mlhpztnzkr) = icttzfxveu bkihbmblsk (yavsvhovvh ) View more	Positive	16 Nov 2010
				Sodium Cromoglicate	myvmxygcqj(mlhpztnzkr) = ouqjdelkyb bkihbmblsk (yavsvhovvh ) View more
ARVO2008	Not Applicable	Uveal Melanoma S100A1	7	Cromolyn	(dinkpxvdok) = zmsszssayv tooalhthia (mdsoadhsmf )	-	01 May 2008
				Artificial tears	(dinkpxvdok) = nhvoptosjc tooalhthia (mdsoadhsmf )
AAAAI2002	Not Applicable	-	-	Delivery agent + Cromolyn	(poxtrfzgpk) = bxgpyyertb nkmzrpoypf (snrkrgaqnd ) View more	-	01 Mar 2002